Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hee Sung Park has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Dong-Il Shin

    Catholic University of Daegu

    3 shared publications
  • Ae Lim Jo

    Catholic Univ Daegu, Dept Pharmaceut Engn, Gyongsan 38430, South Korea

    2 shared publications
  • Bogeun Park

    Division of Applied Life Science (BK21 Four), Plant Molecular Biology and Biotechnology Research Center, Gyeongsang National University, Jinju 52828, Republic of Korea

    2 shared publications
  • Changyul Kim

    Department of Health Management, Daegu Catholic University, Gyeongsan, Republic of Korea

    2 shared publications
  • Jong Chan Hong

    Division of Applied Life Science (BK21 Four), Plant Molecular Biology and Biotechnology Research Center, Gyeongsang National University, Jinju 52828, Republic of Korea

    2 shared publications
  • Nam Ho Jeoung

    Department of Pharmaceutical Science and Technology, Catholic University of Daegu, Gyeongsan, Republic of Korea

    2 shared publications

Latest Publications

  • Open Access

    RETRACTED: Kim et al. Autocrine Motility Factor and Its Peptide Derivative Inhibit Triple-Negative Breast Cancer by Regulating Wound Repair, Survival, and Drug Efflux. Int. J. Mol. Sci. 2024, 25, 11714

    by Se Gie Kim, Seok Joong Kim, Thanh Van Duong, Yuhan Cho, Bogeun Park, Ulhas Sopanrao Kadam, Hee Sung Park, Jong Chan Hong

    The journal retracts the article titled “Autocrine Motility Factor and Its Peptide Derivative Inhibit Triple-Negative Breast Cancer by Regulating Wound Repair, Survival, and Drug Efflux”

  • Open Access

    Autocrine motility factor peptide enhances curcumin/tetrahydrocurcumin activity against colorectal cancer cells in association with glucose-6-phosphate dehydrogenase downregulation and oxidative stress

    by Kyunghee Lee, Yuhan Cho, Dong-Won Bae, Kim-Ngan Thi Nguyen, Changyul Kim, Phil-Ok Koh, Hee Sung Park

    Current therapeutic approaches for colorectal cancer (CRC) face significant limitations, including drug resistance, adverse effects, and high costs. Autocrine motility factor (AMF), the extracellular form of glucose-6-phosphate isomerase, exhibits paradoxical dual functionality as both a growth activator and inhibitor. This study examined the inhibitory effects of tetradecapeptides derived from AMF variants on the proliferation of HT-29 and SW620 CRC cells. Among six AMF peptides tested (AAP, HGP, HTP, SKP, AKP, and KAP), KAP showed the strongest growth inhibition, associated with downregulation of glucose-6-phosphate dehydrogenase (G6PD) and increased reactive oxygen species (ROS) production. Notably, combining KAP with curcumin (CUR) or its derivative tetrahydrocurcumin (THC) markedly reduced the viability of CRC cells that showed limited sensitivity to CUR and THC monotherapy. Furthermore, KAP elevated intracellular accumulation of fluorescent CUR, suggesting possible modulation of membrane transporter activity involved in xenobiotic efflux. These findings suggest that the combination of human-origin AMF peptides and plant-origin CUR/THC may represent a promising natural strategy for CRC treatment, warranting further preclinical investigation.

  • Open Access

    Autocrine Motility Factor-Derived Tetradecapeptides as Dual-Action Chemosensitizers: Bridging Cell Competition Mechanisms with Clinical MDR Reversal in Hematological Malignancies

    by Changyul Kim, Yu Ju Jung, Da Hee Son, Na Young Kim, Se Gie Kim, Hee Sung Park

    Backgrounds: Autocrine motility factor (AMF) represents a paradoxical protein with dual roles in cancer progression and therapy. This study investigated AMF-derived tetradecapeptides as novel chemosensitizing agents to overcome multidrug resistance (MDR) in hematological malignancies (HMs). Methods: Seven AMF variants were screened for anticancer activity across 14 human cancer cell lines using MTT and Cell Counting Kit-8 (CCK-8) assays. Four tetradecapeptides (AMF-derived peptides AAP, HGP, HTP, and SKP) corresponding to the AMF206-219 region were designed and evaluated in three HM cell lines (HL-60, CCRF-CEM, IM-9) for growth inhibition, cellular internalization, reactive oxygen species (ROS) production, mitochondrial membrane potential, and gene/protein expression. Synergism with doxorubicin (DOX) and other chemotherapeutic agents was quantified by combination index (CI) analysis using the Chou-Talalay method and spheroid culture assays. Results: AMF variants demonstrated broad-spectrum anticancer activity, with HL-60 acute promyelocytic leukemia cells showing exceptional sensitivity. AMF variants functioned as cell competition-mediated killing signals, converting cancer cells into metabolically compromised “loser” cells through glucose metabolism disruption and oxidative stress induction. Among the four tetradecapeptides, AAP exhibited the most consistent growth inhibition across HM cell lines (HL-60, CCRF-CEM, IM-9) while maintaining gp78/AMFR-mediated cellular internalization. AAP treatment induced dose-dependent ROS production, mitochondrial membrane potential alterations, and p53 upregulation, though glucose-6-phosphate dehydrogenase (G6PD) suppression showed cell-type specificity. Remarkably, AAP demonstrated potent synergistic effects with DOX, reducing IC50 values by 28–53% across tested HM cells through multiple complementary mechanisms: enhanced intracellular DOX retention, elevated oxidative stress, and downregulation of multidrug resistance protein 1 (MDR1; P-glycoprotein) and multidrug resistance-associated protein 1 (MRP1) in specific cell types. AAP similarly synergized with daunorubicin but not with etoposide or cytarabine, suggesting selectivity for ROS-inducing anthracyclines. Conclusions: These findings establish AMF-derived peptides as promising human-origin chemosensitizers capable of overcoming multidrug resistance in HMs through multi-targeted mechanisms. The ability to reduce anthracycline dosing while maintaining efficacy offers potential for minimizing cardiotoxicity and other dose-limiting adverse effects, warranting further preclinical development toward clinical translation.

  • Open Access

    RETRACTED: Autocrine Motility Factor and Its Peptide Derivative Inhibit Triple-Negative Breast Cancer by Regulating Wound Repair, Survival, and Drug Efflux

    by Se Gie Kim, Seok Joong Kim, Thanh Van Duong, Yuhan Cho, Bogeun Park, Ulhas Sopanrao Kadam, Hee Sung Park, Jong Chan Hong

    Triple-negative breast cancer (TNBC) presents a significant challenge in oncology due to its aggressive nature and limited targeted therapeutic options. This study explores the potential of autocrine motility factor (AMF) and an AMF-derived peptide as novel treatments for TNBC. AMF, primarily secreted by neoplastic cells, plays a crucial role in cancer cell motility, metastasis, and proliferation. The research demonstrates that AMF and its derived peptide inhibit TNBC cell proliferation by modulating cellular migration, redox homeostasis, apoptotic pathways, and drug efflux mechanisms. Dose-dependent antiproliferative effects were observed across three TNBC cell lines, with higher concentrations impairing cellular migration. Mechanistic studies revealed decreased glucose-6-phosphate dehydrogenase expression and elevated reactive oxygen species production, suggesting redox imbalance as a primary mediator of apoptosis. Combination studies with conventional therapeutics showed near-complete eradication of resistant TNBC cells. The observed reduction in p53 levels and increased intranuclear doxorubicin accumulation highlight the AMF/AMF peptide’s potential as multidrug resistance modulators. This study underscores the promise of using AMF/AMF peptide as a novel therapeutic approach for TNBC, addressing current treatment limitations and warranting further investigation.


  • Open Access

    Synergistic Inhibition of Colorectal Cancer Cells by Autocrine Motility Factor Peptide and Glycyrrhetinic Acid

    by Se Gie Kim, Thanh Van Duong, Semin Lee, Ki-Jun Ryu, Hyuk-Kwon Kwon, Hee Sung Park

    Background: Anti-cancer peptides are a powerful drug concept that induces cancer cell death through growth inhibition and membrane disruption, providing broad efficacy. The autocrine motility factor (AMF) interacts with the AMF receptor, regulating cancer cell motility, proliferation, metastasis, and angiogenesis through autocrine and paracrine pathways. However, studies verifying the synergistic effect of the combined use of anti-cancer drugs extracted from plants and AMF treatment are insufficient. Methods: The effects of AMF-derived peptide sequences were evaluated in HT29 and SW620 colorectal cancer (CRC) cell lines. The study assessed the impact of AMF peptides on cell proliferation, colony formation, the Nicotinamide Adenine Dinucleotide Phosphate/Reduced Nicotinamide Adenine Dinucleotide Phosphate (NADP+/NADPH) ratio, and reactive oxygen species (ROS) generation in these CRC cells. Additionally, the combined effect of AMF peptides and glycyrrhetinic acid (GA), a compound derived from licorice plants, was investigated by analyzing cell proliferation, colony formation, ROS production, and cell cycle progression in CRC cells. Results: AMF peptides significantly inhibited CRC cell growth (p < 0.05), decreased colony formation (p < 0.05), and increased the NADP+/NADPH ratio (p < 0.05) and ROS production (p < 0.001). When combined with GA, AMF peptides enhanced GA's effects on CRC cells, further suppressing cell growth (p < 0.05) and colony formation (p < 0.05) while increasing ROS generation (p < 0.05). Conclusion: The synergy between AMF peptides and GA, derived from licorice plants, suggests the potential for combined peptide-phytochemical therapy for treating CRC.


  • Open Access

    Synergistic impact of autocrine motility factor and curcumin on colorectal cancer cell proliferation

    by Seok Joong Kim, Yangji Kim, Thanh Van Duong, Hee Sung Park

    Colorectal cancer (CRC) presents a formidable challenge, characterized by a steadily increasing incidence. Current approaches to manage CRC, including chemotherapy and targeted therapies, are burdened with significant limitations such as resistance development, adverse events, and high costs. Hence, there is an urgent demand for a more promising alternative. Autocrine motility factor (AMF), known for its role in promoting cancer cell motility, exhibits a unique ability to selectively impede the growth of cancer cells. In our study, we have elucidated the specific inhibitory effect of AMF derived from DU145 prostate cancer cells (D-AMF) on the proliferation of CRC cells. D-AMF effectively downregulated the expression of glucose-6-phosphate dehydrogenase (G6PD) at both the mRNA and protein levels, resulting in a concurrent increase in the generation of reactive oxygen species (ROS). Notably, the combination of D-AMF and curcumin proved highly effective in eliminating curcumin-resistant CRC cells. Therefore, the use of D-AMF in conjunction with curcumin holds promise as an alternative treatment approach for CRC.


  • The effect of autocrine motility factor alone and in combination with methyl jasmonate on liver cancer cell growth

    by Nam Ho Jeoung, Ae Lim Jo, Hee Sung Park

    Neoplastic cells secrete autocrine motility factor (AMF) to stimulate the motility of cancer cells. In this study, AMF secreted from HT-29 colorectal cancer cells selectively suppressed liver cancer cells by downregulating pAKT and β-catenin. In addition, HT-29 AMF significantly augmented the activity of methyl jasmonate against liver cancer cells and is a promising alternative for liver cancer therapy.


  • Oral vaccination of mice with Tremella fuciformis yeast-like conidium cells expressing HBsAg

    by Dong-Il Shin, Kyu-Seon Song, Hee-Sung Park

    Tremella fuciformis yeast-like conidium (YLC) cells were transformed by co-cultivation with Agrobacterium cells harboring the hepatitis B surface antigen (HBsAg) gene construct under the control of the CaMV35S promoter. Integration of HBsAg DNA into the YLC genome was confirmed by PCR and dot-blot hybridization. Immunoblotting verified expression of the recombinant protein. Oral administration of YLC cells expressing HBsAg in mice significantly increased anti-HBsAg antibody titer levels using a double prime-boost strategy that combined parenteral and oral HBsAg boosters.